OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Sarcoma"

Survivin, a molecule highly expressed in malignant tumor cells and even some chronic autoimmune disorders, is known for promoting tumor cell growth. Researchers at Columbus Children’s Research Inst ...


Researchers at the University of Michigan ( U-M ) Medical School, in collaboration with researchers at Harvard's Brigham and Women's Hospital, have discovered a recurring pattern of scrambled chromoso ...


Researchers at the Mayo Clinic Cancer Center report that Imatinib ( Glivec, Gleevec ), the drug used to treat patients with gastrointestinal stromal cancers ( GISTs ), is not likely to be effective fo ...


A University of Minnesota Cancer Center study is the first to show how the prevalence of some physical impairments that childhood-cancer survivors experience as adults relate to the type of cancer the ...


A study, published in the Clinical Cancer Research, has showed that Botox may have a new use as an adjuvant to cancer therapy, providing an open door for chemotherapy and radiation treatments. The ...


A phase II study is assessing the safety and efficacy of Sunitinib ( Sutent ) in patients with advanced non-small cell lung cancer ( NSCLC ) that had progressed following standard therapy. “ This ...


Researchers at The University of Texas M. D. Anderson Cancer Center have evaluated a new type of drug that activates "death" receptors on cancer cells, and have found it to be both safe and suggestiv ...


Researchers at National Jewish Medical and Research Center reported in Cancer Research that a pair of promising proteins, known as fibulins 3 and 5, slow the growth of cancer tumors in mice by prevent ...


A study has quantified the risk of hereditary retinoblastoma survivors developing specific subtypes of soft tissue sarcomas and finds that this risk persists for decades after the original retinoblast ...


A dose-intensive regimen of the chemotherapy drugs Cisplatin and Doxorubicin offered no clinical benefit over standard doses of the chemotherapy drugs in patients with a bone cancer called osteosarcom ...


Neuroendocrine tumors ( NETs ) comprise a heterogeneous family of neoplasms with a wide and complex spectrum of clinical behavior. They originate in a great diversity of tissues and are characterized ...


Clinical data for Larotrectinib ( Vitrakvi ), an oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers, were presented at the European Society for Medi ...


Non-clear cell renal cell carcinoma ( NccRCC ) and clear cell renal cell carcinoma with sarcomatoid differentiation ( sccRCC ) have historically been underrepresented in clinical trials. Even with ta ...


The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures ( TLS ), ...


The highly selective TRK inhibitor Larotrectinib ( Vitrakvi ) is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ( ORR ...